RSH Stock Overview An e-health SaaS company, researches, develops, and commercializes medical devices in Australia and the United States. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Respiri Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Respiri Historical stock prices Current Share Price AU$0.067 52 Week High AU$0.10 52 Week Low AU$0.021 Beta -0.28 1 Month Change -11.84% 3 Month Change -18.29% 1 Year Change 179.17% 3 Year Change 34.00% 5 Year Change -20.24% Change since IPO 116.13%
Recent News & Updates
No independent directors Feb 04 Respiri Limited (ASX:RSH) completed the acquisition of Business And Assets of Orb Health Inc. from Orb Health, Inc. Jan 21
No independent directors Dec 24 Respiri Limited (ASX:RSH) entered into a purchase agreement Business And Assets of Orb Health Inc. from Orb Health, Inc. for $9 million. Nov 26
Respiri Limited, Annual General Meeting, Nov 20, 2024 Oct 02
Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.007 loss in FY 2023) Aug 28 See more updates
No independent directors Feb 04 Respiri Limited (ASX:RSH) completed the acquisition of Business And Assets of Orb Health Inc. from Orb Health, Inc. Jan 21
No independent directors Dec 24 Respiri Limited (ASX:RSH) entered into a purchase agreement Business And Assets of Orb Health Inc. from Orb Health, Inc. for $9 million. Nov 26
Respiri Limited, Annual General Meeting, Nov 20, 2024 Oct 02
Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.007 loss in FY 2023) Aug 28 Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million. Jul 23
New major risk - Shareholder dilution Jun 27
New major risk - Share price stability Jun 06 Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.6 million. May 01
New major risk - Financial position Feb 29
Respiri Limited Announces Executive Changes Jan 29 Respiri Limited has completed a Follow-on Equity Offering in the amount of AUD 1.3876 million. Dec 20
Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Dec 16
Less than half of directors are independent Dec 14
Respiri Limited, Annual General Meeting, Nov 15, 2023 Oct 13
Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.009 loss in FY 2022) Sep 01
New major risk - Revenue and earnings growth Aug 31
New minor risk - Financial data availability Aug 30
No independent directors Jun 06
Respiri Limited Appoints Brian Leedman as Non-Executive Director May 24
First half 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in 1H 2022) Mar 03
Respiri Limited Announces Arkansas Heart Hospital Commences Patients on Wheezo RPM Dec 24
Respiri Limited Announces Minnesota Lung Center Wheezo Rpm Pilot Program Patient Selection Has Been Finalised and Patient Onboarding Has Successfully Commence Dec 15
No independent directors Nov 17
Respiri Announces First Patients Enrolled into Wheezo® Remote Patient Monitoring Programs, Further Validating USA Business Model Nov 07
Respiri Limited, Annual General Meeting, Nov 15, 2022 Oct 17
Full year 2022 earnings released Sep 04
Respiri Limited Announces Executive Changes Aug 16
Respiri Limited Announces New £2 Million NIHR-Funded UK Paediatric Asthma Clinical Trial with wheezo Jul 12
Respiri Limited Appoints Brad Snow as A Non-Executive Director Jun 21
Respiri Limited Appoints Brad Snow as A Non-Executive Director Jun 20
Respiri Limited Announces Resignation of Director of Dr. Thomas Duthy Apr 20
First half 2022 earnings: Revenues and EPS in line with analyst expectations Feb 24
Full year 2021 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in FY 2020) Aug 29
Respiri Limited Announces Wheezo Registered and Approved for Sale in the UK Market Jun 12
Insider recently bought AU$95k worth of stock May 29
Respiri Limited (ASX:RSH) made an offer to acquire Adherium Limited (ASX:ADR) from BioScience Managers Translation Fund I and IB Asia Pacific Healthcare Fund II managed by Bioscience Managers Pty Ltd, Regal Funds Management Pty Limited, Trudell Medical Limited, HSBC Custody Nominees (Australia) Limited, Citicorp Nominees Pty Ltd and other shareholders for AUD 15.2 million. May 01
Respiri Limited Announces New Partnership with Pharmacy 4 Less Banner Group Dec 18
Respiri Limited Holds Media Events to Mark the Launch of Wheezo Dec 05
Respiri Limited, Annual General Meeting, Dec 16, 2020 Nov 12
Respiri Limited Files Additional Patent Application Oct 30
Respiri Limited Announces A Partnership with Entech Electronics for the Global Supply of the Ground Breaking Wheezo Sep 22 Respiri Limited to Report Fiscal Year 2020 Results on Aug 25, 2020 Respiri Limited announced that it expects to receive AUD 0.09 million in funding Jun 30
Shareholder Returns RSH AU Medical Equipment AU Market 7D -4.3% -1.9% 0.5% 1Y 179.2% 7.5% 9.9%
See full shareholder returns
Return vs Market: RSH exceeded the Australian Market which returned 8.9% over the past year.
Price Volatility Is RSH's price volatile compared to industry and market? RSH volatility RSH Average Weekly Movement 10.0% Medical Equipment Industry Average Movement 10.2% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.6% 10% least volatile stocks in AU Market 3.0%
Stable Share Price: RSH has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: RSH's weekly volatility (10%) has been stable over the past year.
About the Company Founded Employees CEO Website 1987 n/a Marjan Mikel respiri.co
Respiri Limited, an e-health SaaS company, researches, develops, and commercializes medical devices in Australia and the United States. The company develops, produces, and sells mobile health applications. Its products include wheezo, a wheeze rate detector; respiri mobile application; and Respiri health portal.
Show more Respiri Limited Fundamentals Summary How do Respiri's earnings and revenue compare to its market cap? RSH fundamental statistics Market cap AU$89.40m Earnings (TTM ) -AU$7.13m Revenue (TTM ) AU$1.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RSH income statement (TTM ) Revenue AU$1.04m Cost of Revenue AU$3.86k Gross Profit AU$1.03m Other Expenses AU$8.16m Earnings -AU$7.13m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.0053 Gross Margin 99.63% Net Profit Margin -686.48% Debt/Equity Ratio 41.7%
How did RSH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/06 16:09 End of Day Share Price 2025/02/06 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Respiri Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Soo Romanoff Edison Investment Research
